Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2020-10-20 Regulatory Filings
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces that NANOBIOTIX will present four clinical and preclinical abstracts at the 35th Annual Congress of the Society for Immunotherapy of Cancer (SITC). It details the titles, authors, abstract IDs, and session times for these presentations, which are scheduled for November 2020. This is not a full financial report (10-K or IR), an earnings release (ER), or a management discussion (MDA). It is an announcement about participation in a scientific/investor conference, detailing research findings to be presented. This type of announcement, detailing scientific progress and upcoming presentations, most closely aligns with an Investor Presentation (IP) or a general announcement. Since it is a press release detailing specific research abstracts and conference participation, it serves to inform investors about scientific milestones, making 'Investor Presentation' (IP) the most appropriate fit, as these materials often precede or accompany formal presentations to investors/analysts about R&D progress. It is not a formal regulatory filing (RNS) unless it were a mandatory disclosure, but the content is focused on scientific updates.
2020-10-20 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is explicitly titled '# PRESS RELEASE' and announces that NANOBIOTIX will have four presentations at an upcoming scientific conference (SITC 35th Anniversary Annual Meeting). It details the abstract IDs, dates, and times of these presentations, which relate to clinical and pre-clinical data for their product NBTXR3. This is not a comprehensive annual report (10-K), an interim report (IR), an earnings release (ER), or a formal investor presentation (IP) containing strategy overviews. It is an announcement about scientific data being presented at a third-party event. Since it is a press release announcing scientific/clinical updates, it fits best under the general 'Regulatory Filings' (RNS) category as a general corporate announcement, although it is highly specific. It is not a management change (MANG), director dealing (DIRS), or a dividend notice (DIV). Given the nature of the announcement (a press release detailing presentation abstracts), RNS is the most appropriate general regulatory filing category when a more specific scientific disclosure code is unavailable.
2020-10-20 English
Inside Information / Other news releases
Regulatory Filings Classification · 90% confidence The document is explicitly titled "*PRESS RELEASE*" and announces clinical trial milestones (first patient injected, FDA 'safe to proceed' notifications) related to the drug NBTXR3. This type of announcement, detailing operational and clinical progress, is characteristic of an Earnings Release (ER) or a general regulatory/corporate update. Since it is a press release announcing key operational achievements rather than a full quarterly/annual financial report (10-K or IR), and it is not a transcript (CT) or a specific management discussion (MDA), the most fitting category is Earnings Release (ER), as these often contain operational highlights alongside any financial context, or Regulatory Filing (RNS) as a general announcement. Given the focus on clinical progress and FDA interaction, it functions as a major corporate update. However, ER is typically reserved for financial results. Since this is a press release detailing significant operational/clinical progress, and it is not a proxy statement (DEF 14A), dividend notice (DIV), or a report itself, it fits best as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it were near a reporting period. Since it is a standalone press release announcing clinical progress, RNS is the most appropriate general category for non-standard, material corporate news that isn't explicitly covered elsewhere. Given the options, RNS serves as the best catch-all for material press releases that aren't financial statements or specific transaction reports. However, many companies issue press releases like this alongside or instead of a formal ER. Given the structure and content (major operational update), ER is often used for such announcements, but RNS is safer for non-financial operational news. I will lean towards RNS as the most general fit for a material press release not covered by other specific codes.
2020-10-13 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces clinical trial progress (first patient injection, FDA 'Safe to Proceed' notifications) related to the drug NBTXR3. This type of announcement, detailing operational and clinical milestones rather than comprehensive financial results (like a 10-K or IR) or management changes (MANG), typically falls under general regulatory or corporate news. Since it is a press release announcing specific operational updates (clinical trial progress and regulatory feedback), and it does not fit the definitions for ER (Earnings Release), AR (Audit Report), or CT (Call Transcript), the most appropriate general category for significant, non-financial corporate news that isn't a specific filing type is Regulatory Filings (RNS), which serves as a broad category for miscellaneous regulatory/corporate announcements not covered elsewhere. Given the content is a formal announcement of clinical progress and FDA feedback, RNS is the best fit among the provided options.
2020-10-13 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French regulatory articles (Code de commerce and Règlement Général de l'Autorité des Marchés Financiers - AMF) and provides a table detailing the total number of shares and voting rights as of a specific date (September 30, 2020). This content directly corresponds to notifications regarding changes in the total share capital and voting rights structure, which is a specific type of regulatory disclosure. Among the provided codes, 'SHA' (Share Issue/Capital Change) is the most appropriate fit for reporting the total number of shares and voting rights, as it relates directly to the capital structure.
2020-10-07 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French regulatory articles (Code de commerce and Règlement Général de l'Autorité des Marchés Financiers - AMF) and provides a table detailing the total number of shares and voting rights as of August 31, 2020. This content directly corresponds to notifications regarding changes in the total number of shares and voting rights, which is a specific type of regulatory disclosure. While it is a regulatory filing, the closest specific category that covers changes in share capital structure or related notifications, especially when dealing with voting rights and share counts, is often related to capital changes or major shareholding notifications. However, given the specific nature of reporting the total number of voting rights and shares monthly, this is a standard regulatory disclosure. Reviewing the definitions, 'Major Shareholding Notification' (MRQ) typically relates to crossing ownership thresholds, not the total count. 'Share Issue/Capital Change' (SHA) relates to the action of issuing/changing capital. Since this is a routine monthly disclosure of the *current* total capital/voting rights, and it is a formal regulatory communication, it fits best under the general 'Regulatory Filings' (RNS) as a specific monthly update that doesn't map perfectly to the other specialized categories like DIV, SHA, or MRQ, although it is related to capital structure. However, in many jurisdictions, these monthly voting rights reports are considered a specific type of capital/shareholder structure update. Given the options, and recognizing this is a formal, required regulatory update about the capital base, RNS is the safest fallback. If a more specific category existed for 'Total Voting Rights Disclosure', that would be chosen. Since it is a formal, non-financial, non-management, non-dividend specific regulatory update, RNS is appropriate.
2020-09-10 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.